Sugi Predict

Sugi Predict / Targets / PRKAG3

PRKAG3

5'-AMP-activated protein kinase subunit gamma · Q9UGI9 · PRKAG3 on Sugi Atlas →

44,935 patent compounds predicted against PRKAG3, 27,034 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL518066 SCHEMBL518066 1.00 17/20
SCHEMBL518142 SCHEMBL518142 1.00 17/20
SCHEMBL518266 SCHEMBL518266 0.90 17/20
SCHEMBL518273 SCHEMBL518273 0.79 17/20
SCHEMBL518005 SCHEMBL518005 1.00 16/20
SCHEMBL518045 SCHEMBL518045 1.00 16/20
SCHEMBL518134 SCHEMBL518134 1.00 16/20
SCHEMBL518224 SCHEMBL518224 1.00 16/20
SCHEMBL518225 SCHEMBL518225 1.00 16/20
SCHEMBL518023 SCHEMBL518023 0.93 16/20
SCHEMBL518208 SCHEMBL518208 0.91 16/20
SCHEMBL517797 SCHEMBL517797 0.89 16/20
SCHEMBL517976 SCHEMBL517976 0.89 16/20
SCHEMBL518068 SCHEMBL518068 0.88 16/20
SCHEMBL518179 SCHEMBL518179 0.85 16/20
SCHEMBL517980 SCHEMBL517980 0.84 16/20
SCHEMBL517967 SCHEMBL517967 0.81 16/20
SCHEMBL518037 SCHEMBL518037 0.80 16/20
SCHEMBL518123 SCHEMBL518123 0.79 16/20
SCHEMBL518174 SCHEMBL518174 0.76 16/20

Clinical trials — most relevant to PRKAG3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity PHASE4COMPLETED
Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS) PHASE4RECRUITING
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT) PHASE4UNKNOWN
Metformin Induces a Dietary Restriction-like State in Human PHASE4UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Metformin and Simvastatin Use in Bladder Cancer PHASE2UNKNOWN
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease PHASE2COMPLETED
Effects of Roflumilast on Insulin and Blood Sugar Levels in Prediabetic Overweight and Obese Individuals PHASE1/PHASE2COMPLETED
Efficacy of Amlexanox vs. Placebo in Type 2 Diabetic Patients PHASE2COMPLETED
Safety and Feasibility of Metformin for Sepsis Induced AKI PHASE2COMPLETED
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus PHASE2COMPLETED
Metformin for Fibromyalgia Symptoms (INFORM Trial) PHASE2RECRUITING
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients PHASE1/PHASE2WITHDRAWN
PKC412 and 5-Azacytidine PHASE1/PHASE2COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism. PHASE1COMPLETED
Sirolimus and Gold Sodium Thiomalate in Treating Patients With Advanced Squamous Non-Small Cell Lung Cancer PHASE1WITHDRAWN
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer EARLY_PHASE1COMPLETED
Effect of Age on Glucose and Lipid Metabolism nanCOMPLETED
Intravenous Terbutaline in Severe Status Asthmaticus nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
NASH AMPK Exercise Dosing (AMPED) Trial nanRECRUITING
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States nanCOMPLETED
Skeletal Muscle Mitochondrial Abnormalities and the Metabolic Syndrome in PAH nanCOMPLETED
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men nanRECRUITING
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder. nanCOMPLETED
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation nanCOMPLETED
Influence of Intermittent Hypoxia on Glycemic Control nanCOMPLETED
Defective Atypical Protein Kinase C (PKC) Activation in Diabetes and Metabolic Syndrome nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a PRKAG3 binder may also engage these)

ProteinNameSimilarity
Q2LL38 — 0.997 Q2LL38 →
Q9MYP4 — 0.994 Q9MYP4 →
Q8BGM7 — 0.992 Q8BGM7 →
Q80TM9 — 0.986 Q80TM9 →
Q5R8Z4 — 0.985 Q5R8Z4 →
O93307 — 0.985 O93307 →
BRPF3 Bromodomain and PHD finger-containing protein 3 0.984 landscape →
Q9Z1C8 — 0.984 Q9Z1C8 →
Q8BIA4 — 0.984 Q8BIA4 →
Q5BIW4 — 0.983 Q5BIW4 →
P23348 — 0.983 P23348 →
Q8BMD7 — 0.983 Q8BMD7 →
O75064 — 0.982 O75064 →
Q08274 — 0.982 Q08274 →
Q6QMY5 — 0.982 Q6QMY5 →
Q6QN11 — 0.982 Q6QN11 →
Q9Z1I6 — 0.982 Q9Z1I6 →
Q9WVS8 — 0.982 Q9WVS8 →
Q8TDY4 — 0.982 Q8TDY4 →
Q91ZI8 — 0.982 Q91ZI8 →
A0A1L8F1M4 — 0.981 A0A1L8F1M4 →
Q9H329 — 0.981 Q9H329 →
Q13415 — 0.981 Q13415 →
Q8IY17 — 0.981 Q8IY17 →
A5PK26 — 0.981 A5PK26 →
Q95MN9 — 0.981 Q95MN9 →
NR4A1 Nuclear receptor subfamily 4immunitygroup A member 1 0.981 landscape →
Q80Z32 — 0.981 Q80Z32 →
A1A4J7 — 0.981 A1A4J7 →
Q9R117 — 0.981 Q9R117 →